[
  {
    "ts": null,
    "headline": "Boston Scientific Corp. stock underperforms Friday when compared to competitors",
    "summary": "Boston Scientific Corp. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=95b99b1e4d2befcdf89eb26a04763c5bde64d11b6df7f85cbd5b5402ed39ed68",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761323760,
      "headline": "Boston Scientific Corp. stock underperforms Friday when compared to competitors",
      "id": 137252041,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Boston Scientific Corp. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=95b99b1e4d2befcdf89eb26a04763c5bde64d11b6df7f85cbd5b5402ed39ed68"
    }
  },
  {
    "ts": null,
    "headline": "Why Analysts Are Rethinking Boston Scientific’s Story After Strong Results and Strategic Moves",
    "summary": "Boston Scientific stock is under fresh scrutiny as analysts adjust their price targets upward. The consensus figure is now $126.14, up from $124.53. This incremental rise reflects optimism fueled by strong quarterly results and revised guidance, balanced against an evolving competitive landscape. Read on to discover how you can stay ahead of future updates as the narrative around Boston Scientific continues to develop. What Wall Street Has Been Saying Analyst sentiment on Boston Scientific...",
    "url": "https://finnhub.io/api/news?id=3bad3c6d9e19deeddcc77c53bc1c5ed181286b92d38c2426e28421b742908c58",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761322552,
      "headline": "Why Analysts Are Rethinking Boston Scientific’s Story After Strong Results and Strategic Moves",
      "id": 137216515,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific stock is under fresh scrutiny as analysts adjust their price targets upward. The consensus figure is now $126.14, up from $124.53. This incremental rise reflects optimism fueled by strong quarterly results and revised guidance, balanced against an evolving competitive landscape. Read on to discover how you can stay ahead of future updates as the narrative around Boston Scientific continues to develop. What Wall Street Has Been Saying Analyst sentiment on Boston Scientific...",
      "url": "https://finnhub.io/api/news?id=3bad3c6d9e19deeddcc77c53bc1c5ed181286b92d38c2426e28421b742908c58"
    }
  },
  {
    "ts": null,
    "headline": "UBS Maintains Boston Scientific (BSX) Buy Recommendation",
    "summary": "UBS Maintains Boston Scientific (BSX) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=36caa6323610d9956220487f9d694e7c9f2281638b2baee84d0b855ef0abd230",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761307436,
      "headline": "UBS Maintains Boston Scientific (BSX) Buy Recommendation",
      "id": 137201979,
      "image": "",
      "related": "BSX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=36caa6323610d9956220487f9d694e7c9f2281638b2baee84d0b855ef0abd230"
    }
  },
  {
    "ts": null,
    "headline": "Should Boston Scientific’s (BSX) Upbeat Q3 Results and Raised Guidance Prompt Investor Action?",
    "summary": "Boston Scientific reported third-quarter 2025 results that exceeded analyst expectations, with revenue rising to US$5.07 billion and net income increasing to US$755 million, supported by strong performance across multiple segments and regions. The company raised its financial guidance for the fourth quarter and full year 2025, driven by robust growth in its cardiovascular segment, ongoing product innovation like the FARAPULSE system, and the recent acquisition of Nalu Medical expanding its...",
    "url": "https://finnhub.io/api/news?id=66e8bf9908b9fb2095d72213b34a40348e041c2bddd1d98348716cc1a18376d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761304881,
      "headline": "Should Boston Scientific’s (BSX) Upbeat Q3 Results and Raised Guidance Prompt Investor Action?",
      "id": 137216516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific reported third-quarter 2025 results that exceeded analyst expectations, with revenue rising to US$5.07 billion and net income increasing to US$755 million, supported by strong performance across multiple segments and regions. The company raised its financial guidance for the fourth quarter and full year 2025, driven by robust growth in its cardiovascular segment, ongoing product innovation like the FARAPULSE system, and the recent acquisition of Nalu Medical expanding its...",
      "url": "https://finnhub.io/api/news?id=66e8bf9908b9fb2095d72213b34a40348e041c2bddd1d98348716cc1a18376d7"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific: Continuing Its M&A Playbook, As Organic Achievements Impress",
    "summary": "Boston Scientific shows strong organic growth, margin expansion, and strategic acquisitions, trading at a premium with long-term potential. See why BSX stock is a hold.",
    "url": "https://finnhub.io/api/news?id=e53998069e1841ba47f3e87ef04a40dd32b92512c7b5f9ff3dfd2e1f73bb7dcf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761300678,
      "headline": "Boston Scientific: Continuing Its M&A Playbook, As Organic Achievements Impress",
      "id": 137202321,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217161785/image_2217161785.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Boston Scientific shows strong organic growth, margin expansion, and strategic acquisitions, trading at a premium with long-term potential. See why BSX stock is a hold.",
      "url": "https://finnhub.io/api/news?id=e53998069e1841ba47f3e87ef04a40dd32b92512c7b5f9ff3dfd2e1f73bb7dcf"
    }
  }
]